143 related articles for article (PubMed ID: 29849102)
1. Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions.
Gilbert AN; Anderson JC; Duarte CW; Shevin RS; Langford CP; Singh R; Gillespie GY; Willey CD
Sci Rep; 2018 May; 8(1):8412. PubMed ID: 29849102
[TBL] [Abstract][Full Text] [Related]
2. A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening.
Stackhouse CT; Rowland JR; Shevin RS; Singh R; Gillespie GY; Willey CD
Cells; 2019 Jul; 8(7):. PubMed ID: 31336733
[TBL] [Abstract][Full Text] [Related]
3. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
5. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
[TBL] [Abstract][Full Text] [Related]
6. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
[No Abstract] [Full Text] [Related]
7. Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing.
Gilbert AN; Shevin RS; Anderson JC; Langford CP; Eustace N; Gillespie GY; Singh R; Willey CD
J Vis Exp; 2016 Jun; (112):. PubMed ID: 27341166
[TBL] [Abstract][Full Text] [Related]
8. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.
Xiao W; Zhang R; Sohrabi A; Ehsanipour A; Sun S; Liang J; Walthers CM; Ta L; Nathanson DA; Seidlits SK
Cancer Res; 2018 Mar; 78(5):1358-1370. PubMed ID: 29282221
[TBL] [Abstract][Full Text] [Related]
9. A highly invasive human glioblastoma pre-clinical model for testing therapeutics.
Xie Q; Thompson R; Hardy K; DeCamp L; Berghuis B; Sigler R; Knudsen B; Cottingham S; Zhao P; Dykema K; Cao B; Resau J; Hay R; Vande Woude GF
J Transl Med; 2008 Dec; 6():77. PubMed ID: 19055779
[TBL] [Abstract][Full Text] [Related]
10. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
11. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells.
Matteoni S; Abbruzzese C; Matarrese P; De Luca G; Mileo AM; Miccadei S; Schenone S; Musumeci F; Haas TL; Sette G; Carapella CM; Amato R; Perrotti N; Signore M; Paggi MG
J Exp Clin Cancer Res; 2019 May; 38(1):202. PubMed ID: 31101126
[TBL] [Abstract][Full Text] [Related]
12. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
13. Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo.
Ding Y; Xue Q; Liu S; Hu K; Wang D; Wang T; Li Y; Guo H; Hao X; Ge W; Zhang Y; Li A; Li J; Chen Y; Zhang Q
J Med Chem; 2020 Feb; 63(4):1597-1611. PubMed ID: 31977207
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
15. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
16. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.
Rong X; Huang B; Qiu S; Li X; He L; Peng Y
Oncotarget; 2016 Dec; 7(51):83976-83986. PubMed ID: 27824617
[TBL] [Abstract][Full Text] [Related]
18. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
